Therapy of uveitis in children

International Ophthalmology Clinics

Volumn 48, Issue 3, 2008, Pages 131-152

  Zierhut, Manfred ^a   Doycheva, Deshka ^a   Biester, Sabine ^a   Stüpbiger, Nicole ^a   Kümmerle Deschner, Jasmin ^a   Deuter, Christoph ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; AMPHOTERICIN B; ANTHELMINTIC AGENT; ANTIGLAUCOMA AGENT; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; ETANERCEPT; FLUCYTOSINE; FOLINIC ACID; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; PYRIMETHAMINE SULFADIAZINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RIMEXOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT;

ALOPECIA; AMBLYOPIA; ANAPHYLAXIS; ANEMIA; AZOOSPERMIA; BEHCET DISEASE; BLOOD TOXICITY; CANDIDA ENDOPHTHALMITIS; CATARACT; CHILDHOOD DISEASE; CINCA SYNDROME; CORTICOSTEROID THERAPY; CUSHING SYNDROME; DEPRESSION; DIARRHEA; DRUG BINDING; DRUG WITHDRAWAL; FATIGUE; GLAUCOMA; GUM HYPERPLASIA; HEADACHE; HEMORRHAGIC CYSTITIS; HUMAN; HYPERPLASIA; HYPERTENSION; HYPERTRICHOSIS; INJECTION SITE REACTION; INTERMEDIATE UVEITIS; INTERSTITIAL NEPHRITIS; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; JUVENILE RHEUMATOID ARTHRITIS; LIVER CIRRHOSIS; LIVER TOXICITY; LUNG FIBROSIS; MAINTENANCE THERAPY; MENTAL INSTABILITY; MONOTHERAPY; MORNING DOSAGE; NAUSEA; NEPHROTOXICITY; OVARY DISEASE; PHYSICIAN ATTITUDE; PNEUMONIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RETINA MACULA EDEMA; RETINAL VENOUS THROMBOSIS; REVIEW; SARCOIDOSIS; SIDE EFFECT; SKIN DISEASE; STOMATITIS; TERATOGENICITY; TOXOCARIASIS; TOXOPLASMOSIS; TREMOR; UVEITIS; VITRECTOMY; VOMITING; ADOLESCENT; CHILD; INFANT; PRESCHOOL CHILD;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; PRACTICE GUIDELINES AS TOPIC; UVEITIS;

EID: 51649088277     PISSN: 00208167     EISSN: None     Source Type: Journal    
DOI: 10.1097/IIO.0b013e31817d7107     Document Type: Review

References (85)

1. Edelsten C, Reddy MA, Stanford MR, et al. Visual loss associated with pediatric uveitis in English primary and referral centers. Am J Ophthalmol. 2003; 135:676-680.
2. Paivonsalo-Hietanen T, Tuominen J, Saari KM. Uveitis in children: population-based study in Finland. Acta Ophthalmol Scand. 2000; 78:84-88.
3. Darrell RW, Wagener HP, Kurland LT. Epidemiology of uveitis. Incidence and prevalence in a small urban community. Arch Ophthalmol. 1962; 68:502-514.
4. Zierhut M, Michels H, Stübiger N, et al. Uveitis in children. Int Ophthalmol Clin. 2005; 45:135-156.
5. Cunningham ET Jr. Uveitis in children. Ocul Immunol Inflamm. 2000; 8:251-261.
6. Petty RE, Smith JR, Rosenbaum JT. Arthritis and uveitis in children: a pediatric rheumatology perspective. Am Ophthalmol. 2003; 135:879-884.
7. Michels H, Schuchmann L, Truckenbrodt H, et al. Die rheumatische Iridozyklitis im Kindesalter-Differenzierung nach klinischen und immunologischen Gesichtspunk- ten. Klin Pediatr. 1982; 194:104-108.
8. Chia A, Lee V, Graham EM, et al. Factors related to severe uveitis at diagnosis in children with juvenile idiopathic arthritis in a screening program. Am J Ophthalmol. 2003;135:757-762.
9. Wolf MD, Lichter PR, Ragsdale CG. Prognostic factors in the uveitis of juvenile rheumatoid arthritis. Ophthalmology. 1987; 94:1242-1248.
10. Dana MR, Merayo-Lloves J, Schaumberg DA, et al. Visual outcomes prognosticators in juvenile rheumatoid arthritis-associated uveitis. Ophthalmology. 1997; 104: 236-244.
11. Kotaniemi K, Kautiainen H, Karma A, et al. Occurrence of uveitis in recently diagnosed juvenile chronic arthritis: a prospective study. Ophthalmology. 2001; 108: 2071-2075.
12. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. Br J Ophthalmol. 2007; 91:319-324.
13. Heinz C, Steuhl KP, Heiligenhaus A. Uveitis in childhood sarcoidosis. Klin Monatsbl Augenheilkd. 2005; 222:348-352.
14. Pinar V, Gion N, Foster CS. Tubulointerstinal nephritis and uveitis syndrome. In: Foster CS, Vitale AT, eds. Diagnosis and Treatment of Uveitis. Philadelphia: WB Saunders; 2002:726-730.
15. Goda C, Kotake S, Ichiishi A, et al. Clinical features in tubulointerstitial nephritis and uveitis (TINU) syndrome. Am J Ophthalmol. 2005; 140:637-641.
16. Gion N, Stavrou P, Foster CS. Immunomodulatory therapy for chronic tubulointerstitial nephritis-associated uveitis. Am J Ophthalmol. 2000; 107:764.
17. Neven B, Callebaut I, Prieur AM, et al. Molecular basis of the spectral expression of CIAS1 mutations associated with phagocytic cell-mediated autoinflammatory disorders CINCA/NOMID, MWS, an FGU. Blood. 2004; 102:2808-2815.
18. Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-lbeta inhibition. N Engl J Med. 2006; 355:581-592.
19. Holland GN, Stiehm ER. Special considerations in the evaluation and management of uveitis in children. Am J Ophthalmology. 2003; 135:867-878.
20. Rohrbach JM, Kröber SM, Teufel T, et al. EBV-induced polymorphic lymphoproli- ferative disorder of the iris after heart transplantation. Graefes Arch Clin Exp Ophthalmol. 2004; 242:44-50.
21. Zierhut M, Foster CS. Multiple sclerosis, sarcoidosis and other diseases in patients with pars planitis. Dev Ophthalmol. 1992; 23:41-47.
22. Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986; 102:297-301.
23. Wallon M, Kodjikian L, Binwuet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics. 2004; 113:1567-1572.
24. Deuter CME, Garweg JG, Pleyer U, et al. Ocular toxoplasmosis and toxocariasis in childhood. Klin Monatsbl Augenheilk. 2007; 224:483-487.
25. Maguire AM, Green WR, Michels RG, et al. Recovery of intraocular Toxocara canis by pars plana vitrectomy. Ophthalmology. 1990; 97:675-680.
26. Baley JE, Kliegman RM, Fanaroff AA. Disseminated fungal infections in very low- birth-weight infants: therapeutic toxicity. Pediatrics. 1984; 73:153-157.
27. Annable WL, Kachmer ML, DiMarco M, et al. Long-term follow up of Candida endophthalmitis in the premature infant. J Pediatr Ophthalmol Strabismus. 1990; 27:103-106.
28. Krause I, Uziel Y, Guedj D, et al. Childhood Behçet's disease: clinical features and comparison with adult-onset disease. Rheumatology. 1999; 38:457-462.
29. Guillaume-Czitrom S, Berger C, Pajot C, et al. Efficacy and safety of interferon-α in the treatment of corticodependent uveitis of paediatric Behçet's disease. Rheumatology. 2007; 46:1570-1573.
30. Tugal-Tutkun I, Urgancioglu M. Childhood-onset uveitis in Behçet's disease: a descriptive study of 36 cases. Am J Ophthalmol. 2003;136:1114-1119.
31. Thurau SR, Frosch M, Zierhut M, et al. Topical and systemic corticosteroid therapy for uveitis in childhood. Klin Monatsbl Augenheilkd. 2007;224:516-519.
32. Ozerdem U, Levi L, Cheng L, et al. Systemic toxicity of topical and periocular corticosteroid therapy in an 11-year-old male with posterior uveitis. Am J Ophthalmol. 2000; 130:240-241.
33. Kilmartin DJ, Forrester JV, Dick AD. Cyclosporin A therapy in refractory noninfectious childhood uveitis. Br J Ophthalmol. 1998; 82:737-742.
34. Walton RC, Nussenblatt RB, Whitcup SM. Cyclosporine therapy for severe sight threatening uveitis in children and adolescents. Ophthalmology. 1998; 105:2028-2034.
35. Schlote T, Dannecker G, Thiel HJ, et al. Cyclosporin A in therapy of chronic uveitis in childhood. Ophthalmologe. 1996; 93:745-748.
36. Gerloni V, Cimaz R, Gattinara M, et al. Efficacy and safety profile of cyclosporin A in the treatment of juvenile chronic (idiopathic) arthritis. Results of a 10-year prospective study. Rheumatology. 2001; 40:907-913.
37. Palestine AG, Nussenblatt RB, Chan CC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med. 1984; 77:652-656.
38. Dieterle A, Abeywickrama K, von Graffenried B. Nephrotoxicity and hypertension in patients with autoimmune disease treated with cyclosporine. Transpl Proc. 1988; 20(3 suppl 4):349-355.
39. Kahan BD. Cyclosporine. N Engl J Med. 1989; 321:1725-1738.
40. Hoyer PF, Offner G, Wonigeit K, et al. Dosage of Cyclosporin A in children with retinal transplants. Clin Nephrol. 1984; 22:68-71.
41. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporine A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996; 103:365-374.
42. Feutren G, Mihatsch MJ. Risk factors for cyclosporine-induced nephropathy in patients with autoimmune diseases. International Kidney Biopsy Registry of Cyclosporine in Autoimmune Diseases. N Engl J Med. 1992; 326:1654-1660.
43. Savolainen HA, Kautianen H, Iomaki H, et al. Azathioprine in patients with juvenile rheumatoid arthritis: a long term follow-up study.J Rheumatol. 1997; 24:2444-2450.
44. Silman AJ, Petrie J, Hazleman B, et al. Lymphoproliferative cancer and other malignancy in patients with rheumatoid arthritis treated with azathioprine: a 20 year follow-up study. Ann Rheum Dis. 1988; 47:988-992.
45. Kvien TK, Hoyeraal HM, Sandstad B. Azathioprine versus placebo in patients with juvenile rheumatoid arthritis: a single center double blind comparative study. J Rheumatol. 1986; 13:118-123.
46. Ramadan A, Nussenblatt R. Cytotoxic agents in ocular inflammation. Ophthalmol Clin North Am. 1997; 10:377-387.
47. Schatz CS, Uzel JL, Leininger L, et al. Immunosuppressants used in a steroid-sparing strategy for childhood uveitis.J Pediatr Ophthalmol Stabismus. 2007; 44:28-34.
48. Palmer RG, Kanski JJ, Ansell BM. Chlorambucil in the treatment of intractable uveitis associated with juvenile chronic arthritis. J Rheumatol. 1985; 12:967-970.
49. Miserocchi E, Baltatzis S, Ekong A, et al. Efficacy and safety of chlorambucil in intractable noninfectious uveitis. Ophthalmology. 2002; 109:137-142.
50. Mehra R, Moore TL, Catalano D, et al. Chlorambucil in the treatment of iridocyclitis in juvenile rheumatoid arthritis.J Rheumatol. 1981; 8:141-144.
51. Shah SS, Lowder CY, Schmitt MA, et al. Low-dose methotrexate therapy for ocular inflammatory disease. Ophthalmology. 1992; 99:1419-1423.
52. Foeldvari I, Wierk A. Methotrexate is an effective treatment for chronic uveitis associated with juvenile idiopathic arthritis. J Rheumatol. 2005; 32:362-365.
53. Heiligenhaus A, Mingels A, Heinz C, et al. Methotrexate for uveitis associated with juvenile idiopathic arthritis: value and requirement for additional anti-inflammatory medication. Eur J Ophthalmol. 2007; 17:743-748.
54. Lazar M, Weiner MJ, Leopold IH. Treatment of uveitis with methotrexate. Am J Ophthalmol. 1969;67:383-387.
55. Weiss AH, Wallce CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis.J Pediatr. 1998; 133:266-268.
56. Shetty AK, Zganjar BE, Ellis GS Jr, et al. Low-dose-methotrexate in the treatment of severe juvenile rheumatoid arthritis and sarcoid iritis. J Pediatr Ophthalmol Strabismus. 1999; 36:125-129.
57. Woo P, Southwood TR, Prieur AM, et al. Randomized, placebo controlled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43:1849-1857.
58. Giannini EH, Brewer EJ, Kuzmina N, et al. Methotrexate in resistant juvenile rheumatoid arthritis. Results of the USA-USSR double-blind, placebo-controlled trial. The Pediatric Rheumatology Collaborative Study Group and the Cooperative Children's Study Group. New Engl Med. 1992; 326:1043-1049.
59. Ruperto N, Murray KJ, Gerloni V. Pediatric Rheumatology International Trials Organization. A randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexate. Arthritis Rheum. 2004; 50: 2191-2201.
60. Sengler C, Keitzer R, Pleyer U. Uveitis bei rheumatologischen Erkrankungen im Kindesalter. Ophthalmologe. 2005; 102:463-476.
61. Samson CM, Ekong A, Foster CS. Uveitis in children: diagnosis and management. Int Ophthalmol Clin. 2001; 41:199-216.
62. Allison AC. Mechanisms of action of mycophenolate mofetil. Lupus. 2005; 14:2-8.
63. Smith JM, Nemeth TL, McDonald RA. Current immunosuppressive agents in pediatric renal transplantation: efficacy, side-effects and utilization. Pediatr Transplant. 2004; 8:445-453.
64. Dipchand Al, Benson L, McCrindle BW, et al. Mycophenolate mofetil in pediatric heart transplant recipients: a single-center experience. Pediatr Transplant. 2001; 5: 112-118.
65. Kilmartin DJ, Forrester JV, Dick AD. Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet. 1998; 352:35-36.
66. Larkin G, Lightman S. Mycophenolate mofetil a useful immunosuppressive in inflammatory eye disease. Ophthalmology. 1999; 106:370-374.
67. Siepmann K, Huber M, Stübiger N, et al. Mycophenolate mofetil is a highly effective and safe immunosuppressive agent for the treatment of uveitis: a retrospective analysis of 106 patients. Graefes Arch Clin Exp Ophthalmol. 2006; 244:788-794.
68. Baltatzis S, Tufail F, Yu EN, et al. Mycophenolate mofetil as an immunomodulatory agent in the treatment of chronic ocular inflammatory disorders. Ophthalmology. 2003; 110:1061-1065.
69. Doycheva D, Deuter C, Stuebiger N, et al. Mycophenolate mofetil in the treatment of uveitis in children. Br J Ophthalmol. 2007; 91:180-184.
70. Lacomba MS, Martin CM, Galera JMG, et al. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res. 2001; 33:251-255.
71. Smith JA, Thompson DJ, Whitcup SM, et al. A randomised, placebo-controlled, double-masked clinic trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum. 2005; 53:18-23.
72. Biester S, Michels H, Haefner R, et al. Etanercept in the treatment of chronic anterior uveitis in children. Invest Ophthalmol Vis Sci Abstract ARVO. 2004; 45:2668.
73. Foster CS, Tufail F, Waheed NK, et al. Efficacy of etanercept in preventing relapse of uveitis controlled by methotrexate. Arch Ophthalmol. 2003; 121:437-440.
74. Reddy AR, Backhouse OC. Does etanercept induce uveitis? Br J Ophthalmol. 2003; 87:925.
75. Kaipiainen-Seppänen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthropathy associated with tumour necrosis factor alpha inhibitors. Ann Rheum Dis. 2003; 62:88-89.
76. Saurenmann RK, Levin AV, Rose JB, et al. Comparison of infliximab with etanercept in pediatric uveitis. Graefes Arc Clin Exp Ophthalmol. 2006; 244:281-290.
77. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. Ophthalmology. 2006; 113:308-314.
78. Richards JC, Tay-Kearney ML, Murray K, et al. Infliximab for juvenile idiopathic arthritis-associated uveitis. Clin Exp Ophthalmol. 2005; 33:461-468.
79. Sharma SM, Ramanan AV, Riley P, et al. Use of infliximab in juvenile onset rheumatological disease-associated refractory uveitis: efficacy in joint and ocular disease. Ann Rheum Dis. 2007; 66:840-841.
80. Foeldvari I, Nielsen S, Kümmerle-Deschner J, et al. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.J Rheumatol. 2007; 34:1146-1150.
81. Tynjälä P, Lindahl P, Honkanen V, et al. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis. Ann Rheum Dis. 2007; 66:548-550.
82. Vazquez-Cobian LB, Flynn T, Lehman TJ. Adalimumab therapy for childhood uveitis. J Pediatr. 2006; 149:572-575.
83. Kötter I, Zierhut M, Eckstein AK, et al. Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis. Br J Ophthalmol. 2003; 87:423-431.
84. Deuter CM, Koetter I, Guenaydin I, et al. Interferon alfa-2a: a new treatment option for long lasting refractory cystoid macular edema in uveitis? A pilot study. Retina. 2006; 26:786-791.
85. Tugal-Tutkun I, Gueney-Tefekli E, Urgancioglu M. Results of interferon-alfa therapy in patients with Behçet uveitis. Graefes'Arch Clin Exp Ophthalmol. 2006; 244:1692-1695.